In situ Engineering of Tumor-Associated Macrophages via a Nanodrug-Delivering-Drug (β-Elemene@Stanene) Strategy for Enhanced Cancer Chemo-Immunotherapy,Angewandte Chemie International Edition

当前位置： X-MOL 学术 › Angew. Chem. Int. Ed. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

In situ Engineering of Tumor-Associated Macrophages via a Nanodrug-Delivering-Drug (β-Elemene@Stanene) Strategy for Enhanced Cancer Chemo-Immunotherapy
Angewandte Chemie International Edition ( IF 16.1 ) Pub Date : 2023-06-28 , DOI: 10.1002/anie.202308413
Wei Chen ₁ , Yongjiang Li ₁ , Chuang Liu ₁ , Yong Kang ₂ , Duotian Qin ₁ , Shuying Chen ₁ , Jun Zhou ₁ , Hai-Jun Liu ₁ , Bijan Emiliano Ferdows ₁ , Dylan Neal Patel ₁ , Xiangang Huang ₁ , Seyoung Koo ₁ , Na Kong _{1,

3} , Xiaoyuan Ji _{2,

3} , Yihai Cao ₄ , Wei Tao ₁ , Tian Xie _{3,

5}

Affiliation

The STNSP@ELE strategy, employing 2D stanene-based nanosheets (STNSP) and β-Elemene (ELE), can repolarize tumor-associated macrophages (TAMs) in situ, overcome immunosuppression and enhance chemo-immunotherapy. This study not only demonstrates the therapeutic efficacy of the STNSP-based nanodrug-delivering-drug strategy for immunosuppressive tumors but also establishes general platforms for 2D nanomaterial-mediated cancer chemo-immunotherapy.

中文翻译：

通过纳米药物递送药物 (β-Elemene@Stanene) 策略对肿瘤相关巨噬细胞进行原位工程，以增强癌症化学免疫治疗

STNSP@ELE策略采用2D锡烯基纳米片（STNSP）和β-榄香烯（ELE），可以原位复极肿瘤相关巨噬细胞（TAM），克服免疫抑制并增强化疗免疫治疗。这项研究不仅证明了基于STNSP的纳米药物递送策略对免疫抑制肿瘤的治疗功效，而且还为2D纳米材料介导的癌症化学免疫治疗建立了通用平台。

更新日期：2023-06-28

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南